Urinary biomarkers of bladder cancer: An update and future perspectives

Biomarkers in Medicine

Volumn 7, Issue 5, 2013, Pages 779-790

  Rosser, Charles J ^a,b   Urquidi, Virginia ^b,c   Goodison, Steve ^b,c  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b Nonagen Bioscience Corp   (United States)

^c M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

biomarker; bladder cancer; genomics; metabolomics; proteomics; urinary cytology; urine

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; AURORA A KINASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; NUCLEAR MATRIX PROTEIN 22; PROTEIN HAS2; PROTEIN HYAL1; PROTEIN SERPINA1; RNA; SOMATOMEDIN BINDING PROTEIN 5; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR ETS 2; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER ELISA KIT; CANCER GENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOCYTOCHEMISTRY; METABOLOMICS; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY;

HUMANS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84884572052     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.73     Document Type: Review

References (140)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012
3. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N. Engl. J. Med. 322(16), 1129-1138 (1990
4. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J. Urol. 164(3 Pt 1), 680-684 (2000
5. Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 139(2), 283-285 (1988
6. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: Progression and recurrence. J. Urol. 130(6), 1083-1086 (1983
7. Greene KL, Konety B. Urinary Markers for Bladder Cancer. AUA Update. American Urological Association, MD, USA, 26326-26335 (2007
8. Avritscher EB, Cooksley CD, Grossman HB et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3), 549-553 (2006
9. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 107(5), 982-990 (2006
10. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. Urol. Oncol. 24(4), 338-343 (2006
11. Stein M, Lubetkin D, Taub HC, Skinner WK, Haberman J, Kreutzer ER. The effects of intraurethrallidocaine anesthetic and patient anxiety on pain perception during cystoscopy. J. Urol. 151(6), 1518-1521 (1994
12. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J. Natl Cancer Inst. 95(8), 588-597 (2003
13. Nakamura K, Kasraeian A, Iczkowski KA et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 9, 12 (2009
14. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J. Clin. Oncol. 36(3), 172-175 (2006
15. Raitanen MP, Aine R, Rintala E et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur. Urol. 41(3), 284-289 (2002
16. Friedman GD, Carroll PR, Cattolica EV, Hiatt RA. Can hematuria be a predictor as well as a symptom or sign of bladder cancer? Cancer Epidemiol. Biomarkers Prev. 5(12), 993-996 (1996
17. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J. Occup. Med. 32(9), 838-845 (1990
18. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J. Urol. 148(3), 788-790 (1992
19. Larré S, Catto JW, Cookson MS et al. Screening for bladder cancer: Rationale, limitations, whom to target, and perspectives. Eur. Urol. 63(6), 1049-1058 (2013
20. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol. 37(2), 163-169 (1993
21. Rife CC, Farrow GM, Utz DC. Urine cytology of transitional cell neoplasms. Urol. Clin. North Am. 6(3), 599-612 (1979
22. Shirodkar SP, Lokeshwar VB. Bladder tumor markers: From hematuria to molecular diagnostics-where do we stand? Expert Rev. Anticancer Ther. 8(7), 1111-1123 (2008
23. Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N. Engl. J. Med. 348(23), 2330-2338 (2003
24. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum. Pathol. 21(9), 886-896 (1990
25. Karakiewicz PI, Benayoun S, Zippe C et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 97(5), 997-1001 (2006
26. Trivedi D, Messing EM. Commentary: The role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol. 9, 13 (2009
27. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod. Pathol. 2(Suppl. 2), S53-S59 (2009
28. Gutiérrez Baños JL, del Henar Rebollo Rodrigo M, Antolín Juárez FM, García BM. Usefulness of the BTA stat test for the diagnosis of bladder cancer. Urology 57(4), 685-689 (2001
29. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: A systematic review. Eur. Urol. 47(6), 736-748 (2005
30. Thomas L, Leyh H, Marberger M et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin. Chem. 45(4), 472-477 (1999
31. Mahnert B, Tauber S, Kriegmair M et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)-useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin. Chem. Lab. Med. 41(1), 104-110 (2003
32. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 50(6), 882-887 (1997
33. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J. Urol. 168(2), 465-469 (2002
34. Ramakumar S, Bhuiyan J, Besse JA et al. Comparison of screening methods in the detection of bladder cancer. J. Urol. 161(2), 388-394 (1999
35. Oge O, Kozaci D, Gemalmaz H. The BTA stat test is nonspecific for hematuria: An experimental hematuria model. J. Urol. 167(3), 1318-1319 (2002
36. Hennenlotter J, Huber S, Todenhofer T et al. Point-of-care tests for bladder cancer: The influencing role of hematuria. Adv. Urol. 2011, 937561 (2011
37. Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ. Urinary BTA: Indicator of bladder cancer or of hematuria. World J. Urol. 30(6), 869-873 (2012
38. Ponsky LE, Sharma S, Pandrangi L et al. Screening and monitoring for bladder cancer: Refining the use of NMP22. J. Urol. 166(1), 75-78 (2001
39. Chang YH, Wu CH, Lee YL, Huang PH, Kao YL, Shiau MY. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology 64(4), 687-692 (2004
40. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem. Biophys. Res. Commun. 60(4), 1410-1417 (1974
41. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7), 810-816 (2005
42. Grossman HB, Soloway M, Messing E et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3), 299-305 (2006
43. Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J. Urol. 176(3), 919-926 (2006
44. Shariat SF, Zippe C, Lüdecke G et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or Cis transitional cell carcinoma of the bladder. J. Urol. 173(5), 1518-1525 (2005
45. Hutterer GC, Karakiewicz PI, Zippe C et al. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int. 101(5), 561-565 (2008
46. Schlake A, Crispen PL, Cap AP, Atkinson T, Davenport D, Preston DM. NMP-22, urinary cytology, and cystoscopy: A 1 year comparison study. Can. J. Urol. 19(4), 6345-6350 (2012
47. Huber S, Schwentner C, Taeger D et al. Nuclear matrix protein-22: A prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. 110(5), 699-708 (2012
48. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J. Urol. 162(1), 53-57 (1999
49. Yokoyama T, Sekigawa R, Hayashi T et al. The clinical efficacy of Bladder Chek NMP22 in urothelial cancer. RinshoByori 52(3), 199-203 (2004
50. Atsu N, Ekici S, Oge OO, Ergen A, Hascelik G, Ozen H. False-positive results of the NMP22 test due to hematuria. J. Urol. 167(2), 555-558 (2002
51. Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ. Influencing factors on the NMP-22 urine assay: An experimental model. BMC Urol. 12, 23 (2012
52. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet. Genome Res. 114(3-4), 279-283 (2006
53. Caraway NP, Khanna A, Fernandez RL et al. Fluorescence in situ hybridization for detecting urothelial carcinoma: A clinicopathologic study. Cancer Cytopathol. 118(5), 259-268 (2010
54. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 164(5), 1768-1775 (2000
55. Sarosdy MF, Kahn PR, Ziffer MD et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J. Urol. 176(1), 44-47 (2006
56. Laudadio J, Keane TE, Reeves HM et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice. BJU Int. 96(9), 1280-1285 (2005
57. Halling KC, King W, Sokolova IA et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J. Urol. 167(5), 2001-2006 (2002
58. Riesz P, Lotz G, Paska C et al. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol. Oncol. Res. 13(3), 187-194 (2007
59. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 51(5), 1275-1280 (2007
60. Fritsche HM, Burger M, Dietmaier W et al. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am. J. Clin. Pathol. 134(4), 597-603 (2010
61. Greene KL, Berry A, Konety BR. Diagnostic utility of the ImmunoCyt/uCyt+ test in bladder cancer. Rev. Urol. 8(4), 190-197 (2006
62. Li HX, Li M, Li CL et al. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: A prospective study. Anal. Quant. Cytol. Histol. 32(1), 45-52 (2010
63. Hautmann S, Toma M, Lorenzo Gomez MF et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: A side-by-side comparison. Eur. Urol. 46(4), 466-471 (2004
64. Lodde M, Mian C, Comploj E et al. uCyt+ test: Alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 67(5), 950-954 (2006
65. Messing EM, Teot L, Korman H et al. Performance of urine test in patients monitored for recurrence of bladder cancer: A multicenter study in the United States. J. Urol. 174(4), 1238-1241 (2005
66. Mian C, Maier K, Comploj E et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: An update on 1991 analyses. Cancer 108(1), 60-65 (2006
67. Tetu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod. Pathol. 18(1), 83-89 (2005
68. Toma MI, Friedrich MG, Hautmann SH et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J. Urol. 22(2), 145-149 (2004
69. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20, 686-691 (2001
70. Billerey C, Chopin D, Aubriot-Lorton MH et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955-1959 (2001
71. van Rhijn BW, Lurkin I, Radvanyi F et al. The fibroblast growth factor receptor 3 (I) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61, 1265-1268 (2001
72. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20 (1999
73. van Oers JM, Zwarthoff EC, Rehman I et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur. Urol. 55(3), 650-657 (2009
74. Miyake M, Sugano K, Kawashima K et al. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Biochem. Biophys. Res. Commun. 362(4), 865-871 (2007
75. van Oers JM, Lurkin I, van Exsel AJ et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 11(21), 7743-7748 (2005
76. Miyake M, Sugano K, Sugino H et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci. 101(1), 250-258 (2010
77. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5(11), e13821 (2010
78. van Kessel KE, Kompier LC, de Bekker-Grob EW et al. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: A comparison of 3 strategies. J. Urol. 189(5), 1676-1681 (2013
79. Bakkar AA, Quach V, Le Borgne A et al. Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder. Clin. Chem. 51(8), 1555-1557 (2005
80. Costa VL, Henrique R, Danielsen SA et al. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics 6(9), 1120-1130 (2011
81. Chan MW, Chan LW, Tang NL et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 8(2), 464-470 (2002
82. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res. 10(6), 1887-1893 (2004
83. Renard I, Joniau S, van Cleynenbreugel B et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol. 58(1), 96-104 (2010
84. Scher MB, Elbaum MB, Mogilevkin Y et al. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J. Urol. 188(6), 2101-2107 (2012
85. Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006
86. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancer 94(1), 67-72 (2001
87. van der Aa MN, Zwarthoff EC, Steyerberg EW et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: Feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur. Urol. 55(3), 659-667 (2009
88. Zuiverloon TC, van der Aa MN, van der Kwast TH et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin. Cancer Res. 16(11), 3011-3018 (2010
89. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999
90. Stuart RO, Wachsman W, Berry CC et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc. Natl Acad. Sci. USA. 101, 615-620 (2004
91. LaTulippe E, Satagopan J, Smith A et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002
92. Sun Y, Todorovic S, Goodison S. A feature selection algorithm capable of handling extremely large data dimensionality. Proceedings of: The 8th SIAM International Conference on Data Mining. Atlanta, GA, USA, 24-26 April 2008
93. Sun Y, Goodison S, Li J, Liu L, Farmerie W. Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics 23, 30-37 (2007
94. Blaveri E, Brewer JL, Roydasgupta R et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin. Cancer Res. 11, 7012-7022 (2005
95. Blaveri E, Simko JP, Korkola JE et al. Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11, 4044-4055 (2005
96. Dyrskjot L, Kruhoffer M, Thykjaer T et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64, 4040-4048 (2004
97. Hanke M, Kausch I, Dahmen G, Jocham D, Warnecke JM. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin. Chem. 53(12), 2070-2077 (2007
98. Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J. Urol. 183(2), 493-498 (2010
99. Christoph F, Weikert S, Wolff I et al. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett. 245(1-2), 121-126 (2007
100. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J. Cancer Res. Clin. Oncol. 134(6), 659-665 (2008
101. Dyrskjot L, Thykjaer T, Kruhoffer M et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33, 90-96 (2003
102. Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res. 11, 4029-4036 (2005
103. Dyrskjot L, Zieger K, Real FX, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin. Cancer Res. 13, 3545-3551 (2007
104. Frohlich C, Albrechtsen R, Dyrskjot L, Rudkjaer L, Orntoft TF, Wewer UM. Molecular profiling of ADAM12 in human bladder cancer. Clin. Cancer Res. 12, 7359-7368 (2006
105. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24, 778-789 (2006
106. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168, 93-103 (2006
107. Rosser CJ, Liu L, Sun Y et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol. Biomarkers Prev. 18(2), 444-453 (2009
108. Mengual L, Burset M, Ribal MJ et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin. Cancer Res. 16(9), 2624-2633 (2010
109. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 21(12), 2149-2158 (2012
110. Bhagirath D, Abrol N, Khan R, Sharma M, Seth A, Sharma A. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin. Chim. Acta 413(19-20), 1641-1646 (2012
111. Bongiovanni L, Pirozzi F, Guidi F et al. Bradeion (SEPT4) as a urinary marker of transitional cell bladder cancer: A real-time polymerase chain reaction study of gene expression. J. Urol. 187(6), 2223-2227 (2012
112. Kramer MW, EscuderoDO, Lokeshwar SD et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117(6), 1197-1209 (2011
113. Su L, Cao L, Zhou R et al. Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS. PLoS ONE 8(1), e54237 (2013
114. Bakun M, Niemczyk M, Domanski D et al. Urine proteome of autosomal dominant polycystic kidney disease patients. Clin. Proteomics 9(1), 13 (2012
115. Lei T, Zhao X, Jin S, Meng Q, Zhou H, Zhang M. Discovery of potential bladder cancer biomarkers by comparative urineproteomics and analysis. Clin. Genitourin. Cancer 11(1), 56-62 (2013
116. Majewski T, Spiess PE, Bondaruk J et al. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS ONE 7(8), e42452 (2012
117. Lindén M, Lind SB, Mayrhofer C et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 12(1), 135-144 (2012
118. Chen YT, Chen CL, Chen HW et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J. Proteome Res. 9(11), 5803-5815 (2010
119. Yang N, Feng S, Shedden K et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC-MS/MS and label-free quantification. Clin. Cancer Res. 17(10), 3349-3359 (2011
120. Urquidi V, Goodison S, Ross S, Chang M, Dai Y, Rosser CJ. Diagnostic potential of urinary a1-antitrypsin and apolipoprotein E in the detection of bladder cancer. J. Urol. 188(6), 2377-2383 (2012
121. Hyndman ME, Mullins JK, Bivalacqua TJ. Metabolomics and bladder cancer. Urol. Oncol. 29(5) 558-561 (2011
122. Issaq HJ, Nativ O, Waybright T et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 179(6), 2422-2426 (2008
123. Pasikanti KK, Esuvaranathan K, Ho PC et al. Noninvasive urinary metabolomic diagnosis of human bladder cancer. J. Proteome Res. 9(6), 2988-2995 (2010
124. Park HS, Park WS, Bondaruk J et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J. Natl Cancer Inst. 100(19), 1401-1411 (2008
125. Tilki D, Singer BB, Shariat SF et al. CEACAM1: A novel urinary marker for bladder cancer detection. Eur. Urol. 57(4), 648-654 (2010
126. Eissa S, Labib RA, Mourad MS, Kamel K, El-Ahmady O. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur. Urol. 44(6), 687-694 (2003
127. Shariat SF, Karakiewicz PI, Godoy G et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study. Clin. Cancer Res. 15(22), 7012-7019 (2009
128. Tilki D, Burger M, Dalbagni G et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 60(3), 484-492 (2011
129. Urquidi V, Rosser CJ, Goodison S. Molecular diagnostic trends in urological cancer: Biomarkers for non-invasive diagnosis. Curr. Med. Chem. 19(22), 3653-3663 (2012
130. Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. Eur. Urol. 63(1), 4-15 (2013
131. Nguyen B, Cusumano PG, Deck K et al. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann. Surg. Oncol. 19(10), 3257-3263 (2012
132. Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST. Treatment choices based on OncotypeDx in the breast oncology care setting. J. Cancer Epidemiol. 2012, 941495 (2012
133. Chung W, Bondaruk J, Jelinek J et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev. 20(7), 1483-1491 (2011
134. Holyoake A, O'Sullivan P, Pollock R et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin. Cancer Res. 14(3), 742-749 (2008
135. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS ONE 7(10), e47469 (2012
136. Urquidi V, Kim J, Chang M, Dai Y, Rosser CJ, Goodison S. CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS ONE 7(5), e37797 (2012
137. Urquidi V, Chang M, Dai Y et al. IL-8 as a urinary biomarker for the detection of bladder cancer. BMC Urol. 12(1), 12 (2012
138. Urquidi V, Goodison S, Kim J, Chang M, Dai Y, Rosser CJ. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 79(5), 1185.e1-6 (2012
139. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J. Urol. 167, 75-79 (2002
140. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: Patient perspectives. J. Urol. 177(4), 1277-1282 (2007